HUTCHMED (NASDAQ:HCM) Announces Earnings Results, Misses Expectations By $0.09 EPS

HUTCHMED (NASDAQ:HCM) issued its quarterly earnings data on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.09), FiscalAI reports. The business had revenue of $139.14 million during the quarter, compared to analysts’ expectations of $304.16 million.

Here are the key takeaways from HUTCHMED’s conference call:

• Oncology revenue rose 23% to $162 million in the first half of 2026, supported by strong China sales of ELUNATE and SULANDA and 40% growth in FRUZAQLA global in-market sales. Management maintained its full-year revenue guidance.
• FRUZAQLA’s ex-U.S. geographic expansion drove particularly strong momentum, with sales up 70% outside the U.S.; management expects further growth as additional countries launch the product and secure reimbursement.
• The company reported $16 million of net income and a substantial cash reserve of $1.4 billion, while reiterating its commitment to remain broadly breakeven or profitable as it increases investment in growth programs.
• HUTCHMED advanced its pipeline, with two ATTC assets in global Phase I trials and a third cleared for clinical development. Key savolitinib readouts from the global SAFFRON and China SANOVO studies are expected in the second half, while ATTC clinical data are anticipated in 2027.
• R&D spending increased to $79 million from $72 million as the company invested in ATTC trials, discovery capabilities and AI. Its non-core, low-margin Other Ventures distribution business declined by nearly 20% on a constant-currency basis, partly due to expanded Chinese volume-based procurement.

HUTCHMED Stock Performance

NASDAQ:HCM traded down $0.62 during trading hours on Thursday, hitting $10.77. 59,676 shares of the stock were exchanged, compared to its average volume of 47,249. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $11.02 and its two-hundred day moving average is $13.23. HUTCHMED has a twelve month low of $9.77 and a twelve month high of $18.30.

Institutional Investors Weigh In On HUTCHMED

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its stake in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after acquiring an additional 698 shares during the period. Bank of America Corp DE increased its position in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares during the period. Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after purchasing an additional 5,538 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in HUTCHMED by 19.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. Institutional investors own 8.82% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on HCM shares. Bank of America lowered their target price on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. The Goldman Sachs Group reduced their price target on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. Finally, Weiss Ratings upgraded shares of HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.87.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.